U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07480096) titled 'Efficacy and Safety of Lemborexant for Patients With Cirrhosis and Sleep Problems' on March 13.
Brief Summary: Sleep disturbance poses significant in patients with liver cirrhosis and is associated with impaired quality of life and worsening clinical status. Current pharmacological options remain limited and often have safety concerns due to altered hepatic metabolism. Lemborexant, a dual orexin receptor antagonist, promotes physiological sleep by inhibiting orexin-mediated wakefulness pathways. This study aims to evaluate the efficacy and safety of lemborexant for improving sleep in patients with liver cirrhosis.
Study Start Date...